Analysis ReGen Biologics, Inc. (RGBOQ)
5/27/2024
Analysis of ReGen Biologics, Inc. (RGBOQ)
ReGen Biologics, Inc. (RGBOQ) has been trading at a consistent price of 0.00080 for the past several days. The Relative Strength Index (RSI) indicator, Moving Average Convergence Divergence (MACD) indicator, and Moving Averages (MA) indicators are all showing values of 0.00000, indicating a lack of significant movement or trend in the stock price.Overall, based on the available data, it appears that ReGen Biologics, Inc. is currently experiencing a period of stability with no clear signals of a bullish or bearish trend. It would be important to monitor the stock for any changes in indicators or price movements that could signal a shift in the stock's direction.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, and total debt to equity MRQ is 140.968.
- Profit margin: 26.306%
- Fiscal year ends: September 30, 2023
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.44, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%
- Return on assets TTM: 22.073999%
- Return on equity TTM: 147.25%
Stock statistics:
- Short ratio: 1.66
- Float shares: 15,308,320,742
- Shares short: 94,308,265
- Average 10-day volume: 52,903,608
- Average 90-day volume: 62,823,269
- Shares outstanding: 15,334,099,968
- Percent held by insiders: 5.22%
- Percent held by institutions: 57.555%
- Short percent of shares outstanding: 0.62%
Valuation metrics:
- PEG ratio: 26.213001
- Forward PE: 26.213001
- Trailing PE: 29.428572
- Enterprise value: $2,948,462,018,560
- Price to book MRQ: 39.181313
- Price to sales TTM: 7.6151557
- Enterprise to EBITDA: 22.745
- Enterprise to revenue: 7.726
- Market capitalization: $2,906,118,684,672
Stock price summary:
- Beta: 1.264
- 50-day moving average: $173.6936
- 200-day moving average: $180.7906
- Fifty-two week low: $164.08
- Fifty-two week high: $199.62
- Fifty-two week change: 8.253%
Dividends and splits:
- Payout ratio: 14.93%
- Dividend date: May 16, 2024
- Last split date: August 31, 2020
- Ex-dividend date: May 10, 2024
- Last split factor: 4-for-1 split
- Forward annual dividend rate: $1
- 5-year average dividend yield: 0.73%
- Forward annual dividend yield: 0.5266761603816345%
- Trailing annual dividend rate: $0.97
- Trailing annual dividend yield: 0.5108758755701854%
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.33.Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023, indicating overall profitability growth.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, reflecting strong operational performance.
8. The company's tax expenses have also increased in line with the growth in revenue and income.
9. Overall, the financial performance of the company seems to be positive, with a focus on revenue growth, cost management, and profitability.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been increasing over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been paying a significant amount in income taxes each year, with a slight decrease in 2020.
4. Interest paid has also varied, with a noticeable increase in 2023 compared to previous years.
5. The company has been actively involved in financing activities, including common stock repurchases, debt issuances, and dividends.
6. Investing activities have seen fluctuations, particularly in the sale and purchase of investments.
7. The end cash position has been fluctuating, with a decrease in 2020 followed by an increase in the following years.
These conclusions provide insights into the company's financial performance and strategic decisions over the years.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing an increase compared to the year-ago EPS figures, indicating potential growth in earnings for the company.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year and 9.7% in the next year.
- For the current quarter, the growth rate is estimated to be 5.6%, while for the next quarter it is projected to be 4.8%.
- Over the next 5 years, the company is expected to achieve an annual growth rate of 11%.
- In the past 5 years, the company has achieved an annual growth rate of approximately 20.1%.
Overall, the company is expected to maintain a positive growth trajectory, with a slightly higher growth rate projected for the next 5 years compared to the historical performance.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions regarding the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price of the security is $191.57, which is below the median and average forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
MACD of RGBOQ
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
